COVID-19 Vaccine Governance Licensing Pharmaceutical Industry 
Bill of Health
AUGUST 29, 2022
On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. government funding, announced that it felt “a special obligation … to use our resources to bring this pandemic to an end as quickly as possible.” By Jorge L. Updating” the Pledge.
Bill of Health
SEPTEMBER 28, 2023
Such a provision could prevent the public from paying twice for publicly-funded medical products—first through their taxes subsidizing government funded research and development, and second to procure the product in an inflated U.S. pharmaceutical market. Moreover, the NASDAQ Biotechnology Index increased by 374% from 1995 to 2000.
Expert insights. Personalized for you.
362 
Let's personalize your content